cardiology - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,823 +0.60%

DJIA 48,234 +0.68%

Nasdaq 25,032 +0.56%

DAX 23,865 -0.41%

Gold $4,196 +0.16%

Oil $98.17 +1.53%

BTC $71,885 +0.73%

VIX 20.63 -15.03%

EUR/USD 1.1785 -0.02%

ETH $2,207 -0.09%

S&P 500 6,823 +0.60%

DJIA 48,234 +0.68%

Nasdaq 25,032 +0.56%

DAX 23,865 -0.41%

Gold $4,196 +0.16%

Oil $98.17 +1.53%

BTC $71,885 +0.73%

VIX 20.63 -15.03%

EUR/USD 1.1785 -0.02%

ETH $2,207 -0.09%

cardiology

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

Can the CRISPR Therapeutics Pipeline in cardiology turn today’s modest gene-editing revenues into a multi-billion-dollar growth story? Maik Kemper Editor in Chief Conclusion In summary,…